CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump

Slides:



Advertisements
Similar presentations
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Advertisements

Steroids In caRdiac Surgery (SIRS) Trial
Is this the “spioenkop” for CABG?
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
5 Years Results of Off-Pump VS On-Pump CABG 5 Years Results of Off-Pump VS On-Pump CABG Prospective Non-randomized Comparative Study Piya Cherntanomwong*,
Population Health Research Institute Hamilton Health Sciences/McMaster University Hamilton, Canada Steroids In caRdiac Surgery (SIRS) Trial SIRS was funded.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
The Heart Outcomes Prevention Evaluation (HOPE) – 3 Trial
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
The Heart Outcomes Prevention Evaluation (HOPE) – 3 Trial
Angela Aziz Donnelly April 5, 2016
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
David J McCormack MFSTEd FRCSEd (CTh) Advanced Clinical Fellow
The German Off-Pump Coronary Artery Bypass Grafting in
Single IMA {Single Arterial}
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Why Radial Access Should be the Default for Women undergoing PCI?
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Andre Lamy on behalf of the COMPASS Investigators
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
Balloon-pump assisted Coronary Intervention Study (BCIS-1):
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.
Jeff Macemon Waikato Cardiothoracic Unit
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,
Dabigatran in myocardial injury after noncardiac surgery
The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
The Hypertension in the Very Elderly Trial (HYVET)
Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,
American College of Cardiology Presented by Dr. Stephan Windecker
Dr. PJ Devereaux on behalf of POISE Investigators
A Systematic Review and Meta-analysis of Randomized Trials of Manual Thrombectomy in ST elevation myocardial infarction Investigators: Ashraf Alazzoni,
AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
for the REGROUP Trial Investigators
On behalf of all principal COMPARE II investigators:
Dr. PJ Devereaux on behalf of POISE Investigators
Dabigatran in myocardial injury after noncardiac surgery
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Dabigatran in myocardial injury after noncardiac surgery
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presenter Disclosure Information
Presentation transcript:

CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study Results at 1 Year André Lamy PopulationHealth Research Institute HamiltonHealth Sciences McMasterUniversity Hamilton,CANADA on behalfof the CORONARY Investigators Disclosures: CORONARY was funded by a grant from the Canadian Institutes of Health Research (CIHR).

• Benefits and risks of performing CABG surgery on Background • Benefits and risks of performing CABG surgery on beating heart (off pump) not clearly established. • Meta-analyses of 59 trials involving 8961 pts – No differences in major CV outcomes except strokes • ROOBY (1 Year) – Primary Outcome: Off-pump is worse (p=0.04) – CV Deaths: Off-pump is worse (p=0.03) 2

• 4,752 patients recruited between (November 2006 CORONARY Trial Organization • 79 centers in 19 countries • 4,752 patients recruited between (November 2006 October 2011) • Designed, coordinated, managed and data analysed and reported by the Population Health Research Institute, Hamilton Health Sciences and McMaster University in Hamilton, Canada • The data was monitored by independent DSMB • Funded by Canadian Institutes of Health Research 3

- Off pump CABG compared to on-pump CABG Study Hypotheses - Off pump CABG compared to on-pump CABG would reduce major clinical events in short-term (30 Days) - Benefits maintained in long-term (5 yrs) 4

Peripheral vascular disease Cerebrovascular disease Inclusion/Exclusion Criteria • Inclusion Criteria – Isolated CABG with median sternotomy – One of the following: 1. 2. 3. 4. 5. 6. Peripheral vascular disease Cerebrovascular disease Renal Insufficiency Age ≥ 70 years Age 60 -69 with at least one risk factor (diabetes, urgent revascularization, smoker, LVEF ≤ 35%) Age 55 -59 with at least two of the above risk factors • Exclusions – Additional cardiac procedure planned – Contraindications to off-pump or on-pump CABG – Emergency or re-do CABG 5

• Surgical expertise-based randomization Qualifications of Surgeons • Surgical expertise-based randomization –> 2 years of experience as staff cardiac surgeon and –> 100 cases of one or both techniques –Trainees were not allowed to be primary operators 6

• 1st Co-Primary Outcome Primary Outcomes • 1st Co-Primary Outcome Composite of total mortality, stroke, non fatal myocardial infarction, new renal failure at 30 days post randomization results presented ACC 2012 results at 1 year • 2nd Co-Primary Outcome Composite of above outcomes plus repeat coronary revascularization over 5 yrs of follow-up (expected 2016) 7

• Secondary Efficacy Outcomes Other Outcomes – 1 Year • Secondary Efficacy Outcomes - Components of 1st co-Primary Outcome - Revascularization • Other Outcomes - Recurrent angina, and CV mortality - Quality of life, neurocognitive function 8

• 1st Co-Primary Outcome Statistical Power • 1st Co-Primary Outcome Composite of total mortality, stroke, non fatal myocardial infarction, new renal failure at 30 days post randomization 80% power to detect a 28% risk reduction • 2nd Co-Primary Outcome Composite of above outcomes plus repeat coronary re-revascularization over 5 yrs of follow-up (expected 2016) 90% power to detect a 20% risk reduction 9

Baseline Characteristics OFF-PUMP (n=2375) ON-PUMP (n=2377) MeanAge(years) 67.6 67.5 Males(%) 80.0 81.7 PriorMI 33.8 35.2 PreviousStroke 6.7 7.8 PeripheralArterialDisease 8.0 8.2 CongestiveHeartFailure 5.9 6.6 UrgentSurgery 39.5 38.1 Euroscore 0–2 3–5 >5 28.6 51.7 18.1 27.8 54.2 16.8 10

Baseline Disease – Pre-op Angiogram OFF-PUMP (n=2375) % ON-PUMP (n=2377) LeftMain 22.1 20.9 TripleVessel 56.1 60.4 DoubleVessel 18.7 16.4 SingleVessel 3.0 2.1 11

Operation Details 4752Randomized(ITTAnalyses) OffPump OnPump CABG≤30days 2148(90.4%) 2183(91.8%) Cross-overs 184(7.8%) 150(6.4%) % RR 95%CI pvalue Incompleterevascularization 11.8 10.0 1.18 1.00-1.39 0.05 Operatingroom(medianhrs) 4.0 4.2 <0.001 Initialventilation(medianhrs) 9.6 11.2 12

1st Co-Primary Outcome (1 Year) OffPump % OnPump Hazard Ratio 95%CI p value PrimaryOutcome Death,Stroke,MI,RenalFailure 12.1 13.3 0.91 0.77-1.07 0.24 13

1st Co-Primary Outcome (1 Year) OffPump % OnPump Hazard Ratio 95%CI p value PrimaryOutcome Death,Stroke,MI,RenalFailure 12.2 13.3 0.91 0.77-1.07 0.24 Components Death 5.2 5.0 1.03 0.80-1.32 Stroke 1.5 1.7 0.90 0.57-1.41 NonFatalMI 6.8 7.5 0.73-1.12 NewRenalFailure 1.3 0.97 0.59-1.60 14

Death/MI/Stroke/New Renal Failure at 1 Year 0.20 0.15 On Pump CABG Off Pump CABG HR 0.91 95% CI 0.77-1.07 p value 0.24 Cumulative Event Rate 0.10 0.05 0.0 3 6 9 12 15

Other Outcomes at 1 year OffPump % OnPump Hazard Ratio 95%CI pvalue CardiovascularMortality 4.2 4.0 1.03 0.78-1.37 0.83 Angina 1.0 0.9 1.05 0.58-1.88 0.87 PCI 1.1 0.8 1.43 0.79-2.57 0.23 Re-doCABG 0.3 0.04 7.00 0.86-57.0 0.07 PCI/Re-doCABG 1.4 1.66 0.95-2.89 PrimaryOutcomeperProtocol 11.5 13.2 0.86 0.73-1.02 0.08 16

Primary Outcome between 31 days and 1 Year OffPump % OnPump Hazard Ratio 95%CI p value PrimaryOutcome Death/MI/Stroke/RenalFailure 2.6 3.2 0.79 0.55-1.13 0.19 Components Death 2.1 2.4 0.87 0.58-1.31 Stroke 0.5 0.6 0.83 0.36-1.92 NonFatalMI 0.2 0.4 0.50 0.15-1.65 NewRenalFailure 0.1 0.09—2.71 17

Other Outcomes between 31 days and 1 Year OffPump % OnPump Hazard Ratio 95%CI pvalue CardiovascularMortality 1.5 1.06 0.65-1.73 0.82 Angina 0.8 0.7 1.13 0.56-2.26 0.74 PCI 0.6 1.15 0.55-2.41 0.72 Re-doCABG <0.1 0.99 PCI/Re-doCABG 1.22 0.59-2.54 0.59 18

Quality of Life 19

Neurocognitive Function 20

Subgroups (1) 21

Subgroups (2) 22

• At 1 Year there was no difference between Off Conclusions • At 1 Year there was no difference between Off pump CABG and On pump CABG: – Primary Outcome – Individual components of the Primary Outcome – Revascularization procedures – Quality of Life – Neurocognitive functions 23

Implications • In experienced hands, both procedures are reasonable options based on mid-term results 24

Steering Committees A.Lamy(Co-PI) D.P.Taggart P.J.Devereaux D.Prabhakaran J.Murkin R.J.Novick A.R.Akar S.E.Fremes E.Paolasso A.Avezum S.Hu L.Piegas R.Cartier F.Lanas Z.Straka S.Chocron P.J.Lopez S.Yusuf(co-PI) 25

Final Recruitment by Country 4752 patients from 79 sites in 19 countries Netherlands (27) Sweden (56) United Kingdom (227) France (4) Italy (48) Canada (830) Czech Republic (298) Estonia (91) Turkey (132) USA (68) Ukraine (11) China (781) India (1307) Colombia (57) Brazil (358) Australia(29) Chile (137) Uruguay (34) Argentina (257) 26

27